Ropes Wealth Advisors’s AstraZeneca AZN Stock Holding History

Ropes Wealth Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$222K	Sell	1,639 -140	-8%	-$19.1K	0.04%	241
2023 Q2	$255K	Hold	1,779	–	–	0.04%	243
2023 Q1	$247K	Sell	1,779 -190	-10%	-$25.6K	0.04%	241
2022 Q4	$267K	Buy	+1,969	New	+$247K	0.05%	235
2021 Q1	–	Sell	-1,248	Closed	-$125K	–	292
2020 Q4	$125K	Buy	1,248 +513	+70%	+$54.3K	0.02%	285
2020 Q3	$81K	Hold	735	–	–	0.02%	291
2020 Q2	$78K	Sell	735 -72	-9%	-$7.44K	0.02%	275
2020 Q1	$72K	Hold	807	–	–	0.02%	254
2019 Q4	$80K	Hold	807	–	–	0.02%	291
2019 Q3	$72K	Buy	807 +347	+75%	+$30.1K	0.02%	307
2019 Q2	$38K	Hold	460	–	–	0.01%	365
2019 Q1	$37K	Hold	460	–	–	0.01%	363
2018 Q4	$35K	Hold	460	–	–	0.01%	334
2018 Q3	$36K	Buy	460 +260	+130%	+$19.7K	0.01%	358
2018 Q2	$14K	Sell	200 -27	-12%	-$1.94K	﹤0.01%	444
2018 Q1	$16K	Buy	227 +27	+14%	+$1.87K	﹤0.01%	420
2017 Q4	$14K	Hold	200	–	–	﹤0.01%	491
2017 Q3	$14K	Buy	+200	New	+$12.6K	﹤0.01%	468

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Ropes Wealth Advisors's AZN Position: Q3 2023 in Review

Ropes Wealth Advisors reduced its AstraZeneca (AZN) stake by 7.9% in Q3 2023, selling an estimated $19.1K and leaving 1,639 shares worth $222K. The position accounts for 0.04% of the portfolio, ranked #241.

Ropes Wealth Advisors first reported a position in AZN in Q3 2017 and has held it in 18 quarters since. The position peaked at $267K in Q4 2022. 1,073 funds tracked by Wall St. Rank hold AZN as of Q3 2023.

Ropes Wealth Advisors held 1,639 shares of AstraZeneca worth $222K as of Q3 2023.
Ropes Wealth Advisors sold 140 AstraZeneca shares in Q3 2023, an estimated $19.1K.
AstraZeneca made up 0.04% of Ropes Wealth Advisors's portfolio in Q3 2023, its #241 holding.
Ropes Wealth Advisors first reported a position in AstraZeneca in Q3 2017 and has held it in 18 quarters since.
Ropes Wealth Advisors's AstraZeneca position peaked at $267K in Q4 2022.
1,073 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2023.

Based on Ropes Wealth Advisors's 13F filing for Q3 2023, filed 19 Oct 2023.